Sandeep Jani, MD
Advanced Heart Failure and Transplant Cardiology · Baltimore, MDNPI 1750549333
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $68,035 of the $75,400 with a category attached, or 90.2%. E.r. Squibb & Sons, L.L.C. accounts for 73.9% of it on its own, with 18 other manufacturers making up the rest.
Across 119 payments — averaging $633.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$56K
- Pfizer$14K
- Bridgebio Pharma, Inc.$2K
- Akcea Therapeutics, Inc.$2K
- Abbott$401
- Abiomed$194
- plus $681 from 13 others
Across 158 payments — averaging $1679.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$81K
- Boehringer Ingelheim Pharma GmbH & Co.kg$65K
- Novartis$46K
- E.r. Squibb & Sons, L.L.C.$41K
- Lexicon Pharmaceuticals, Inc.$23K
- Eidos Therapeutics, Inc.$10K
What the payments were for
- Consulting fees$2,6764%
- Speaking & faculty fees$68,03590%
- Travel & lodging$1,0831%
- Food & beverage$3,5935%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 58 | $55,711 |
| Pfizer | 17 | $14,043 |
| Bridgebio Pharma, Inc. | 3 | $2,186 |
| Akcea Therapeutics, Inc. | 5 | $2,183 |
| Abbott | 5 | $401 |
| Abiomed | 2 | $194 |
| Novartis | 5 | $128 |
| United Therapeutics Corporation | 4 | $113 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $75 |
| Medtronic | 2 | $66 |
| AstraZeneca | 3 | $63 |
| Amicus Therapeutics, Inc. | 2 | $53 |
| Lexicon Pharmaceuticals, Inc. | 2 | $47 |
| Cvrx, Inc. | 1 | $30 |
| Bristol Myers Squibb | 1 | $28 |
| Boehringer Ingelheim | 1 | $22 |
| Novo Nordisk | 1 | $22 |
| Johnson & Johnson | 1 | $18 |
| Merck | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few advanced heart failure and transplant cardiology providers in Marylandto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 110 | $3,123,366 |
| EntrestoSacubitril/Valsartan | 364 | $545,376 |
| JardianceEmpagliflozin | 213 | $295,953 |
| EliquisApixaban | 182 | $244,522 |
| CamzyosMavacamten | 27 | $216,686 |
| FarxigaDapagliflozin Propanediol | 98 | $110,909 |
| XareltoRivaroxaban | 37 | $59,538 |
| Metoprolol Succinate | 285 | $4,430 |
| Amiodarone Hcl | 120 | $3,791 |
| Eplerenone | 36 | $3,234 |
| Potassium Chloride | 68 | $3,014 |
| Carvedilol | 256 | $2,889 |
| Atorvastatin Calcium | 258 | $2,787 |
| Torsemide | 116 | $2,723 |
| Spironolactone | 308 | $2,531 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $14,043 | $3,367,889292 claims |
| NovartisEntresto | $128 | $545,376364 claims |
| Boehringer IngelheimJardiance | $22 | $295,953213 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $55,711 | $216,68627 claims |
| AstraZenecaFarxiga | $63 | $110,90998 claims |
| Johnson & JohnsonXarelto | $18 | $59,53837 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Marylandon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Baltimore
- Susan JosephBaltimore$65K
- Kavita SharmaBaltimore$63K
- Gautam RamaniBaltimore$32K
- Joban VaishnavBaltimore$30K
- Luigi AdamoBaltimore$9K
- Mohammad Sadegh AsadiBaltimore$7K
- Steven HsuBaltimore$4K
- Weining XuBaltimore$2K
- Nisha GilotraBaltimore$718
- Virginia HahnBaltimore$256
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.